Compare Medpace Holdings Inc (MEDP) vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $64.51 (market cap $394.18M). The key difference: Medpace Holdings Inc is far larger — about 42.7× Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 for 63 Days on average.
| MEDP | SLVO | |
|---|---|---|
Market Cap | $16.82B | $394.18M |
Volume | 223,093 | 84,843 |
Sector | Health | Income / Options Overlay |
52-Week High | $630.19 | $107.41 |
52-Week Low | $393.42 | $61.81 |
Typical Hold Time | 14 Days | 63 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
SLVO trades at $64.59, up 1.62% today but remains in a bearish technical trend, with moving averages signaling continued downward pressure. Financial ratios are not available, limiting fundamental clarity. Recent news highlights the stock crossing below its 50-day moving average and links its performance to silver price declines, indicating sensitivity to commodity markets.
The outlook is cautious due to bearish technicals and commodity volatility. Opportunities exist if silver prices stabilize, but risks include dollar strength and lack of fundamental data. Investors should weigh technical recovery potential against macroeconomic headwinds affecting silver.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033
SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →
